These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11571722)

  • 1. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features.
    Iyoda A; Hiroshima K; Toyozaki T; Haga Y; Baba M; Fujisawa T; Ohwada H
    Cancer; 2001 Sep; 92(5):1108-12. PubMed ID: 11571722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma.
    Iyoda A; Hiroshima K; Moriya Y; Iwadate Y; Takiguchi Y; Uno T; Nakatani Y; Yoshino I
    J Thorac Cardiovasc Surg; 2009 Aug; 138(2):446-53. PubMed ID: 19619794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
    Kozuki T; Fujimoto N; Ueoka H; Kiura K; Fujiwara K; Shiomi K; Mizobuchi K; Tabata M; Hamazaki S; Tanimoto M
    J Cancer Res Clin Oncol; 2005 Mar; 131(3):147-51. PubMed ID: 15538626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases.
    Veronesi G; Morandi U; Alloisio M; Terzi A; Cardillo G; Filosso P; Rea F; Facciolo F; Pelosi G; Gandini S; Calabrò F; Casali C; Marulli G; Spaggiari L
    Lung Cancer; 2006 Jul; 53(1):111-5. PubMed ID: 16697073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
    Eba J; Kenmotsu H; Tsuboi M; Niho S; Katayama H; Shibata T; Watanabe S; Yamamoto N; Tamura T; Asamura H; ;
    Jpn J Clin Oncol; 2014 Apr; 44(4):379-82. PubMed ID: 24474818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy.
    Tanaka Y; Ogawa H; Uchino K; Ohbayashi C; Maniwa Y; Nishio W; Nakao A; Yoshimura M
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):839-46. PubMed ID: 22498090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K; Laskin J; Ho C
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
    J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection.
    Zacharias J; Nicholson AG; Ladas GP; Goldstraw P
    Ann Thorac Surg; 2003 Feb; 75(2):348-52. PubMed ID: 12607637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
    Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
    J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.
    Kujtan L; Muthukumar V; Kennedy KF; Davis JR; Masood A; Subramanian J
    J Thorac Oncol; 2018 May; 13(5):707-714. PubMed ID: 29391287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical study of advanced large cell neuroendocrine carcinoma].
    Kishi K; Homma S; Takaya H; Miyamoto A; Sakamoto S; Kurosaki A; Motoi N; Yoshimura K
    Nihon Kokyuki Gakkai Zasshi; 2006 Aug; 44(8):556-60. PubMed ID: 16972612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
    Booth CM; Shepherd FA; Peng Y; Darling G; Li G; Kong W; Mackillop WJ
    J Thorac Oncol; 2012 Mar; 7(3):559-66. PubMed ID: 22307012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
    Couillard-Montminy V; Gagnon PY; Fortin S; Côté J
    J Oncol Pharm Pract; 2019 Jan; 25(1):44-51. PubMed ID: 28825377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
    J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.